placebo once weekly

DRUG2 trials

Sponsors

AstraZeneca, Lumara Health, Inc.

Conditions

EndometriosisType 2 Diabetes Mellitus

Phase 2

Pain Associated With Endometriosis

CompletedNCT00758953

Lumara Health, Inc.Endometriosis

Start: 2007-02-28End: 2009-01-31Updated: 2012-03-06

Phase 3

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

CompletedNCT00637273

AstraZenecaType 2 Diabetes Mellitus

Start: 2008-01-31End: 2009-07-31Updated: 2015-04-07

Related Papers

Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease

Diabetes Therapy2020-04-189 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.

2013-05-0151 citations

Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.

2013-05-016 citations

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.

2013-03-2312 citations

Development and validation of the self-management profile for type 2 diabetes (SMP-T2D).

2012-10-0516 citations

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

2010-06-26444 citations